title: First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma.
authors.affiliation: Department of Hematology, Gustave Roussy, Villejuif, France.
authors.forename: D
authors.initials: D
authors.lastname: Ghez
authors.affiliation: EORTC Headquarters, Brussels, Belgium.
authors.forename: C
authors.initials: C
authors.lastname: Fortpied
authors.affiliation: Department of Onco-Hematology, CHU l'Archet, Nice, France.
authors.forename: N
authors.initials: N
authors.lastname: Mounier
authors.affiliation: Department of Hematology, Gustave Roussy, Villejuif, France.
authors.forename: P
authors.initials: P
authors.lastname: Carde
authors.affiliation: Department of Hematology, CHU Nancy-Brabois, Vandoeuvre Les Nancy, France.
authors.forename: A
authors.initials: A
authors.lastname: Perrot
authors.affiliation: Department of Medical Oncology, National Cancer Institute, Cairo, Egypt.
authors.forename: H
authors.initials: H
authors.lastname: Khaled
authors.affiliation: Department of Oncology and Hematology, Hopital Saint-Louis APHP, Université Paris Diderot, Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Amorim
authors.affiliation: EORTC Headquarters, Brussels, Belgium.
authors.forename: S
authors.initials: S
authors.lastname: Ramadan
authors.affiliation: Unité Hémopathies Lymphoïdes, Hôpital Henri Mondor, Creteil, France.
authors.forename: F L
authors.initials: FL
authors.lastname: Bras
authors.affiliation: Department of Oncology, Umea Universitet, Umea, Sweden.
authors.forename: M
authors.initials: M
authors.lastname: Erlanson
authors.affiliation: Department of Clinical Hematology, Hôpital Claude Huriez, Université de Lille 2, Lille, France.
authors.forename: C
authors.initials: C
authors.lastname: Herbaux
authors.affiliation: Department of Hematology, CHU Amiens, Université Picardie Jules Verne, Amiens, France.
authors.forename: J-P
authors.initials: JP
authors.lastname: Marolleau
authors.affiliation: Department of Hematology, Leon Bérard Cancer Center, Lyon, France.
authors.forename: E
authors.initials: E
authors.lastname: Nicolas-Virelezier
authors.affiliation: Department of Hematology, CHU Dijon, Dijon, France.
authors.forename: O
authors.initials: O
authors.lastname: Casasnovas
authors.affiliation: Department of Hematology, Centre Henri Becquerel, Rouen, France.
authors.forename: A
authors.initials: A
authors.lastname: Stamatoullas-Bastard
authors.affiliation: Department of Hematology, Gustave Roussy, Villejuif, France.
authors.forename: C
authors.initials: C
authors.lastname: Fermé
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D064592:Autografts; D018572:Disease-Free Survival; D019650:Hematopoietic Stem Cell Mobilization; D006689:Hodgkin Disease / Q000097:blood / Q000401:mortality / Q000628:therapy; D006801:Humans; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D013234:Stem Cells; D015996:Survival Rate